Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(TEVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
8.59(c) 8.25(c) 8.18(c) 8.16(c) 8.05(c) Last
17 542 872 14 705 080 11 919 603 11 097 766 12 982 331 Volume
+1.18% -3.96% -0.85% -0.24% -1.35% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 16 222 M - -
Net income 2021 903 M - -
Net Debt 2021 21 746 M - -
P/E ratio 2021 11,3x
Yield 2021 -
Sales 2022 16 304 M - -
Net income 2022 1 295 M - -
Net Debt 2022 19 624 M - -
P/E ratio 2022 8,71x
Yield 2022 -
Capitalization 8 879 M 8 879 M -
EV / Sales 2021 1,89x
EV / Sales 2022 1,75x
Nbr of Employees 37 736
Free-Float 90,1%
More Financials
Company
Teva Pharmaceutical Industries Limited is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active... 
Sector
Pharmaceuticals
Calendar
02/10Earnings Release
More about the company
Ratings of Teva Pharmaceutical Industries Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about TEVA PHARMACEUTICAL INDUSTRIES LIMITED
12/02Teva Announces Launch of an Authorized Generic of Epiduo Forte Gel (adapalene and benzo..
AQ
12/01Teva Launches Epiduo Forte Gel's Generic Version in US
MT
12/01Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benz..
BU
11/25Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.
AQ
11/24TEVA PHARMACEUTICAL INDUSTRIES LTD : Change in Directors or Principal Officers (form 8-K)
AQ
11/24Teva Pharmaceutical Industries Limited Announces Change in Chief Accounting Officer
CI
11/18Immuneering Announces Participation in December Investor Conferences
AQ
11/10TEVA PHARMACEUTICAL INDUSTRIES LTD : Entry into a Material Definitive Agreement, Creation ..
AQ
11/10Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum T..
AQ
11/10Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum T..
BU
11/10Teva Pharmaceutical Industries Limited Announces Early Tender Results of Its Debt Tende..
CI
11/10Immuneering to Participate in Jefferies 2021 London Healthcare Conference
AQ
11/09Oklahoma Supreme Court Throws Out $465 Million Opioid Lawsuit Against Johnson & Johnson
MT
11/08From Clinical Trial Efficacy to Real-World Effectiveness First AJOVY® ▼ (fremanez..
BU
11/08Teva Germany Presented At the DGN Congress 2021 the First Interim Analysis Results of t..
CI
More news
News in other languages on TEVA PHARMACEUTICAL INDUSTRIES LIMITED
12/01Teva lance la version générique du gel Epiduo Forte aux États-Unis
11/26Les valeurs à suivre aujourd'hui à la Bourse de Paris Vendredi 26 novembre 2021
11/26A suivre aujourd'hui
11/25Les valeurs à suivre demain à la Bourse de Paris Vendredi 26 novembre 2021
11/25QUANTUM GENOMICS : licence exclusive avec Teva Israel
More news
Analyst Recommendations on TEVA PHARMACEUTICAL INDUSTRIES LIMITED
More recommendations
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | TEVA | US8816242098 | MarketScreener
Technical analysis trends TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 8,05 $
Average target price 11,47 $
Spread / Average Target 42,5%
EPS Revisions
Managers and Directors
Kåre Schultz President, Chief Executive Officer & Director
Eli Kalif Chief Financial Officer & Executive Vice President
Sol J. Barer Chairman
Hafrun Fridriksdottir Executive VP-Global Research & Development
Eric Drapé Executive Vice President-Global Operations
Sector and Competitors
1st jan.Capi. (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-16.58%8 879
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641